Recruiting
Phase 1

LY4560736

Sponsor:

Eli Lilly and Company

Code:

NCT07843459

Conditions

Healthy Volunteers

Alzheimer Disease

Amyloid

Plaque, Amyloid

Plasma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

LY4560736

LY4560736

Placebo

Placebo

Florbetapir F18

Study Details

Brief summary:

The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.

Conditions

Healthy Volunteers

Alzheimer Disease

Amyloid

Plaque, Amyloid

Plasma

Study ID

NCT07843459

Start date

Oct 7, 2026

Status verified date

Nov, 2026

Completion date

Jul, 2028

Anticipated

Primary completion date

Jul, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Participants must meet eligibility criteria in the A1D-MC-ATMP screening protocol before entry into the treatment study.
  • To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
  • To qualify as Chinese for this study, all four of the participant's biological grandparents must be of exclusive Chinese descent and born in China.

Exclusion Criteria:

  • Have a condition that predisposes the participant to an infection.
  • Have a current or recent acute, active infection.
  • Have active tuberculosis (TB), have or have had latent TB.
  • Are receiving therapeutic antibodies or expected to initiate treatment with therapeutic antibodies during the study.

Study Design

Enrollment

111 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: LY4560736 Part A: Single-Ascending Dose (SAD)

LY4560736 administered intravenously (IV) or subcutaneously (SC) in healthy volunteers.

placebo comparator: Placebo Part A

Placebo administered IV or SC in healthy volunteers.

experimental: LY4560736 Part B: Multiple Ascending Dose (MAD)

LY4560736 administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan.

placebo comparator: Placebo Part B

Placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid PET scan.

Interventions

LY4560736

Administered intravenously (IV)

LY4560736

Administered subcutaneously (SC)

Placebo

Administered IV

Placebo

Administered SC

Florbetapir F18

Administered IV

Florbetaben F 18

Administered IV

Primary outcome measure

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to 13 Weeks ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

CenExel ACT

Recruiting

Anaheim, California, United States, 92801

Contacts

Principal Investigator:

Amina Haggag

Collaborative Neuroscience Network - CNS

Recruiting

Los Alamitos, California, United States, 90720

Contacts

Principal Investigator:

Steven Reynolds

Fortrea Clinical Research Unit

Recruiting

Daytona Beach, Florida, United States, 32117

Contacts

Principal Investigator:

Chiamaka Iheme

More Information

Sponsor

Eli Lilly and Company

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.